Stock Taper
Inspire Medical Systems develops minimally invasive neurostimulation solutions, including the Inspire system, to treat moderate to severe obstructive sleep apnea globally.

The Inspire V is an FDA-approved implantable neurostimulation system for OSA that monitors breathing, stimulates a nerve to keep the airway open, integrates a respiratory sensor, and features a Bluetooth remote for patients.
| Icon | PRODUCT | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
![]() | Operating Segment | $224.5M | $269.08M ▲ | $204.58M ▼ | $200.58M ▼ |
| Map | REGION | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
![]() | UNITED STATES | $214.39M | $256.94M ▲ | $195.6M ▼ | $187.3M ▼ |
![]() | NonUS | $10.11M | $12.14M ▲ | $8.98M ▼ | $13.28M ▲ |
Overall rating: A+
| PEER | PRICE | |
|---|---|---|
ITGR | $125.33 | COMPARE |
RCUS | $29.21 | COMPARE |
BKD | $11.72 | COMPARE |
ADUS | $115.55 | COMPARE |
LMAT | $80.45 | COMPARE |
ARDT | $10.96 | COMPARE |
AORT | $26.77 | COMPARE |
PRCT | $20.83 | COMPARE |